December 3-5, 2014, Bethesda, Maryland
As stated by the SUO, the needs and the objectives of the 15th Annual Meeting prostate cancer sessions acknowledge that, “Prostate cancer is the most commonly diagnosed cancer in men and the second leading cause of male cancer death. Controversy remains regarding if population-based screening for prostate cancer is beneficial, how screening might best be performed (which markers and how should they be utilized), how to best manage low-risk prostate cancer, how to incorporate MRI into screening, the role of PET CT scanning and surgical resection in the management of men with biochemical recurrence, and the role of surgery in men with bone mets. The conference will also review new concepts in the pathophysiology of the metabolic syndrome, management of CRPCa, and immunotherapy developments.
“This year’s prostate cancer sessions will provide important information to physicians in order that they may provide patients with the best treatment options and outcomes.”
Included in the presentations will be one from Fred Saad, MD, FRCSC, of the University of Montreal. Dr. Saad, a member of the Australian-Canadian Prostate Cancer Research Alliance, will present final analysis results from the COU-AA-302 trial. The randomized, phase 3 trial of abiraterone acetate (AA) plus prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer patients demonstrated statistically significant overall survival benefit in patients who took AA + prednisone compared with those who took placebo plus prednisone.
A printed recap of the conference will be polybagged with upcoming issues of The Lancet Oncology and Urology (The Gold Journal).